Please assess the completion status of the following clinical trial:

Trial Title: Safety and IOP-Lowering Effects of WB007

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Ocular hypertension or primary open-angle glaucoma in each eye~Exclusion Criteria:~* History of orthostatic hypotension~* Any active ocular disease~* Anticipated wearing of contact lenses during study~* Contraindication to pupil dilatation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Period 1): WB007 0.05% (Type: EXPERIMENTAL): WB007 0.05%, single dose to study eye on Day 1
- Part 1 (Period 2): WB007 0.15% (Type: EXPERIMENTAL): WB007 0.15%, single dose to study eye on Day 1
- Part 1 (Period 3): WB007 0.4% (Type: EXPERIMENTAL): WB007 0.4%, single dose to study eye on Day 1
- Part 2: WB007 0.15% (Type: EXPERIMENTAL): WB007 0.15%, dosed twice daily for 14 days
- Part 2: WB007 0.4% (Type: EXPERIMENTAL): WB007 0.4%, dosed twice daily for 14 days
- Part 2: Timolol 0.5% (Type: ACTIVE_COMPARATOR): Timolol 0.5%, dosed twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).